Clinical Benefit of Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer
Author Information
Author(s): Salah-Eddin Al-Batran, Joachim Bischoff, Günter von Minckwitz, A. Atmaca, U. Kleeberg, I. Meuthen, G. Morack, W. Lerbs, D. Hecker, J. Sehouli, A. Knuth, E. Jager
Primary Institution: Krankenhaus Nordwest, Frankfurt, Germany
Hypothesis
Does pegylated liposomal doxorubicin (PLD) provide clinical benefit in patients with metastatic breast cancer previously treated with anthracyclines?
Conclusion
PLD was associated with an evident clinical benefit in anthracycline-pretreated patients with metastatic breast cancer.
Supporting Evidence
- The overall clinical benefit rate was 24%.
- Median time to progression was 3.6 months.
- Median overall survival was 12.3 months.
- 14 patients (17.7%) had a prolonged clinical benefit lasting ≥12 months.
Takeaway
This study looked at how well a special type of cancer medicine works for women with breast cancer who had already tried other treatments. It found that some women did get better with this new medicine.
Methodology
79 women with metastatic breast cancer received PLD 50 mg/m² every 4 weeks, and their responses were assessed.
Limitations
The study was limited to patients who had previously received anthracyclines, which may not represent all metastatic breast cancer patients.
Participant Demographics
Median age was 58 years, with a range of 35-79 years; 82.6% had visceral disease.
Statistical Information
P-Value
p=0.024
Confidence Interval
95% CI 14.6–33.4%
Statistical Significance
p=0.024
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website